论文部分内容阅读
目的观察阿德福韦酯联合微卡、乙肝疫苗治疗慢性乙型肝炎临床效果。方法 85例慢性乙型肝炎患者,按照治疗方法不同分为参照组(43例)和研究组(42例)。参照组患者采用阿德福韦酯片治疗,研究组患者在参照组治疗基础上联合微卡、乙肝疫苗治疗。比较两组治疗效果及安全性。结果研究组治疗总有效率为95.2%,高于参照组的76.7%,差异具有统计学意义(χ~2=5.9936,P=0.0143<0.05)。两组不良反应发生率比较差异无统计学意义(χ~2=1.0360,P=0.3087>0.05)。结论慢性乙型肝炎采用阿德福韦酯联合微卡、乙肝疫苗治疗效果显著,安全性高,具有积极的临床选择和推广价值。
Objective To observe the clinical effect of adefovir dipivoxil combined with micro-card and hepatitis B vaccine in the treatment of chronic hepatitis B patients. Methods Eighty-five patients with chronic hepatitis B were divided into the reference group (43 cases) and the study group (42 cases) according to the different treatment methods. Reference group patients treated with adefovir dipivoxil tablets, the study group patients in the reference group based on the combination of micro-card, hepatitis B vaccine treatment. The curative effect and safety of the two groups were compared. Results The total effective rate of the study group was 95.2%, which was significantly higher than that of the reference group (76.7%) (χ ~ 2 = 5.9936, P = 0.0143 <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (χ ~ 2 = 1.0360, P = 0.3087> 0.05). Conclusion Adefovir dipivoxil combined with Mika and Hepatitis B vaccine have significant therapeutic effect and high safety in chronic hepatitis B patients, and have positive clinical value and promotion value.